VICTORIA – My Next Health Inc., a subsidiary of Victoria’s Green Sky Labs, has secured a $150 million equity capital commitment through a share subscription facility entered into with Luxembourg-based GEM Global Yield LLC SCS , a private alternative investment group.
GEM has agreed to purchase, for a period of 36 months after a public listing of MNH’s common stock, up to $150 million in shares from time to time upon MNH’s drawdown request under the agreement.
“Securing this capital commitment from the GEM Group propels us forward on the path to improving human health by accelerating the world’s transition to precision medicine,” Chief Executive Officer of My Next Health, Dr. Richard Heinzl, stated. “Working with a strong capital partner like the GEM Group is a valuable support to our business strategy as we look forward to achieving significant corporate objectives in the coming months.”
Global Emerging Markets is a $3.4 billion alternative investment group with offices in Paris, New York, and Nassau in the Bahamas. GEM manages a diverse set of investment vehicles focused on emerging markets and has completed over 480 transactions in 70 countries. Each investment vehicle has a different degree of operational control, risk-adjusted return, and liquidity profile.
My Next Health Inc. vision is to improve human health and accelerate the world’s transition to precision medicine through ground-breaking clinical trials and digital therapeutic platforms.
This will be done using unique functional genomics insights derived from thousands of case studies into the associations between genes, metabolic pathways and health outcomes.
